Nuvalent sank -5.6% this morning, compared to the S&P 500's day change of -0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Nuvalent has logged a 94.2% 52 week change, compared to 39.8% for the S&P 500
-
NUVL has an average analyst rating of buy and is -14.8% away from its mean target price of $113.55 per share
-
Its trailing earnings per share (EPS) is $-2.79, which brings its trailing Price to Earnings (P/E) ratio to -34.7. The Health Care sector's average P/E ratio is 26.07
-
The company's forward earnings per share (EPS) is $-4.28 and its forward P/E ratio is -22.6
-
The company has a Price to Book (P/B) ratio of 9.83 in contrast to the Health Care sector's average P/B ratio is 3.53
-
The current ratio is currently 22.8, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $-99739000 and the average free cash flow growth rate is -172.4%